問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site > 收納受試者人數排名

Search Result

List

44Cases

2015-12-22 - 2015-12-22

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects with Chronic Hepatitis B and who are currently not on Treatment

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    GS-9620,Tenofovir Disoproxil Fumarate (TDF)

Participate Sites
3Sites

Not yet recruiting1Sites

Terminated2Sites

莊萬龍
Kaohsiung Municipal Gangshan Hospital

Digestive System Department

2018-08-28 - 2021-04-12

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Antiviral Activity of GS-9688 in Viremic Adult Subjects with Chronic Hepatitis B who are not currently on Treatment

  • Condition/Disease

    Viremic Chronic Hepatitis B

  • Test Drug

    GS-9688 Film-coated Tablets, 1.5mg

Participate Sites
5Sites

Terminated3Sites

莊萬龍
Kaohsiung Municipal Gangshan Hospital

未分科

2017-06-01 - 2019-12-31

Phase II

Placebo-controlled, Double-blind, Randomized Study of Aerucin® as Adjunct Therapy to Antibiotics in the Treatment of P. Aeruginosa Pneumonia

  • Condition/Disease

    Pseudomonas Aeruginosa Pneumonia

  • Test Drug

    Aerucin（aerubumab，AR-105）

Participate Sites
11Sites

Terminated10Sites

許超群
Kaohsiung Municipal Gangshan Hospital

未分科

2017-02-17 - 2020-12-17

Phase III

Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease

  • Condition/Disease

    Active Crohn’s Disease

  • Test Drug

    Filgotinib, 100 mg and 200 mg per tablet

Participate Sites
14Sites

Recruiting9Sites

Terminated3Sites

吳登強
Kaohsiung Municipal Gangshan Hospital

未分科

邱正堂
Linkou Chang Gung Medical Foundation

2018-01-01 - 2020-05-01

Phase III

A phase 3, randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of Pimodivir combined with standard care treatment in adolescents, adults, and elderly hospitalized patients with influenza A

  • Condition/Disease

    Influenza A Infection

  • Test Drug

    Pimodivir

Participate Sites
5Sites

Terminated4Sites

許超群
Kaohsiung Municipal Gangshan Hospital

未分科

2016-01-01 - 2017-12-08

Phase III

A Randomized, Double-Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects With Ulcerative Colitis

  • Condition/Disease

    Ulcerative Colitis

  • Test Drug

    ENTYVIO; KYNTELES

Participate Sites
5Sites

Terminated4Sites

吳登強
Kaohsiung Municipal Gangshan Hospital

未分科

2015-12-01 - 2021-12-31

Phase III

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer′s Disease

  • Condition/Disease

    Alzheimer′s disease

  • Test Drug

    Aducanumab

Participate Sites
8Sites

Terminated7Sites

劉景寬
Kaohsiung Municipal Gangshan Hospital

未分科

劉景寬
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2017-01-13 - 2023-12-31

Phase III

A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FLT3/ITD AML in First Complete Remission

  • Condition/Disease

    Acute Myeloid Leukemia

  • Test Drug

    ASP2215

Participate Sites
7Sites

Terminated5Sites

蕭惠樺
Kaohsiung Municipal Gangshan Hospital

未分科

2016-11-01 - 2022-02-28

Phase III

A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer

  • Condition/Disease

    Metastatic Colorectal Cancer

  • Test Drug

    LGX818 ( Encorafenib) , MEK162( Binimetinib)

Participate Sites
8Sites

Terminated6Sites

王照元
Kaohsiung Municipal Gangshan Hospital

未分科

邱昌芳
China Medical University Hospital-Taipei

未分科

2017-12-01 - 2019-12-31

Phase III

Multi-center, partially blinded, randomized, 24-week, parallel grouping, non-inferiority, open-label, active controlled trial, comparing the efficacy and safety of QVM149 with salmeterol/fluticasone + tiotropium triple combination therapy for patients with poorly controlled asthma

  • Condition/Disease

    Asthma

  • Test Drug

    QVM149

Participate Sites
9Sites

Terminated7Sites

許超群
Kaohsiung Municipal Gangshan Hospital

未分科

杭良文
China Medical University Hospital-Taipei

未分科

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB